A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Recruiting · NCT05732103 · Registry updated 2026-04-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-13 | NCT05732103 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chordia Therapeutics, Inc. | 1 |
| Theradex | 4 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Seattle | United States | 250 |
| Mayo Clinic Arizona | Phoenix | United States | 55 |
| Mayo Clinic Comprehensive Cancer Center | Rochester | United States | 6 |
| Mayo Clinic Florida | Jacksonville | United States | 105 |
| Northwestern University | Chicago | United States | 727 |
| The University of Rochester | Rochester | United States | 1 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |
| University of Virginia | Charlottesville | United States | 136 |